Table 4.
Co-expression of activated AKT and PI3K with ER and PGR and their prediction for DSS in patients with non-GIST STSs (univariate analyses; log-rank test, n = 249, only significant combinations are represented) and results of Cox regression analysis (multivariate analyses).
| Univariate analyses | Multivariate analyses | |||||||
|---|---|---|---|---|---|---|---|---|
|
Markers coexpression |
Patients (n) |
Patients (%) |
Median survival (months) |
5-Year survival (%) |
P | Hazard ratio | 95% CI | P |
| ER/p-Akt Thr308 all | ||||||||
| -/- | 83 | 33 | 127 | 57 | 0.002 | NS | ||
| -/+ | 58 | 23 | 18 | 29 | ||||
| +/- | 42 | 17 | 63 | 54 | ||||
| +/+ | 47 | 19 | 45 | 46 | ||||
| Missing | 19 | 8 | ||||||
| ER/p-Akt Thr308 women | ||||||||
| -/- | 42 | 30 | 57 | 50 | 0.012 | NS | ||
| -/+ | 35 | 25 | 16 | 27 | ||||
| +/- | 27 | 19 | 91 | 59 | ||||
| +/+ | 25 | 19 | 120 | 53 | ||||
| Missing | 11 | 7 | ||||||
| PgR/p-Akt Thr308 all | ||||||||
| -/- | 101 | 41 | 127 | 59 | 0.014 | NS | ||
| -/+ | 62 | 25 | 26 | 38 | ||||
| +/- | 26 | 10 | 54 | 46 | ||||
| +/+ | 49 | 20 | 32 | 32 | ||||
| Missing | 11 | 4 | ||||||
| PgR/p-Akt Thr308 men | ||||||||
| -/- | 49 | 45 | NR | 64 | 0.003 | 1.0 | 0.099* | |
| -/+ | 30 | 27 | 29 | 43 | 2.0 | 1.0-4.1 | 0.047 | |
| +/- | 8 | 7 | 15 | 25 | 1.8 | 0.65-4.8 | 0.261 | |
| +/+ | 17 | 16 | 17 | 18 | 2.4 | 1.1-5.2 | 0.023 | |
| Missing | 6 | 5 | ||||||
| ER/p-Akt Ser473 women | ||||||||
| -/- | 18 | 13 | 127 | 63 | 0.006 | NS | ||
| -/+ | 58 | 41 | 16 | 32 | ||||
| +/- | 14 | 10 | 62 | 56 | ||||
| +/+ | 37 | 27 | 91 | 55 | ||||
| Missing | 13 | 9 | ||||||
| PgR/p-Akt Ser473 men | ||||||||
| -/- | 29 | 27 | NR | 55 | 0.010 | 1.0 | 0.022* | |
| -/+ | 51 | 47 | NR | 57 | 1.1 | 0.54-2.4 | 0.744 | |
| +/- | 4 | 4 | 21 | 0 | 6.7 | 1.9-24 | 0.003 | |
| +/+ | 21 | 19 | 15 | 24 | 1.5 | 0.67-3.2 | 0.329 | |
| Missing | 5 | 5 | ||||||
| ER/PI3K all | ||||||||
| -/- | 65 | 27 | 127 | 60 | 0.002 | 1.0 | 0.032* | |
| -/+ | 73 | 29 | 18 | 36 | 2.0 | 1.2-3.2 | 0.005 | |
| +/- | 33 | 13 | NR | 63 | 1.1 | 0.56-2.1 | 0.816 | |
| +/+ | 56 | 22 | 37 | 43 | 1.4 | 0.83-2.4 | 0.200 | |
| Missing | 22 | 9 | ||||||
| ER/PI3K women | ||||||||
| -/- | 33 | 24 | 100 | 59 | <0.001 | 1.0 | 0.036* | |
| -/+ | 42 | 30 | 15 | 25 | 2.4 | 1.2-4.8 | 0.014 | |
| +/- | 23 | 16 | NR | 70 | 0.9 | 0.36-2.0 | 0.715 | |
| +/+ | 29 | 21 | 29 | 46 | 1.5 | 0.72-3.0 | 0.290 | |
| Missing | 13 | 9 | ||||||
| PgR/PI3K all | ||||||||
| -/- | 76 | 31 | NR | 62 | 0.001 | 1.0 | 0.032* | |
| -/+ | 86 | 35 | 29 | 43 | 1.9 | 1.2-3.0 | 0.007 | |
| +/- | 26 | 10 | 100 | 58 | 1.3 | 0.69-2.5 | 0.397 | |
| +/+ | 46 | 18 | 31 | 27 | 1.9 | 1.1-3.2 | 0.014 | |
| Missing | 15 | 6 | ||||||
| PgR/PI3K men | ||||||||
| -/- | 36 | 34 | NR | 65 | 0.014 | NS | ||
| -/+ | 44 | 40 | 63 | 51 | ||||
| +/- | 7 | 6 | 21 | 29 | ||||
| +/+ | 15 | 14 | 17 | 20 | ||||
| Missing | 7 | 6 | ||||||
| PgR/PI3K women | ||||||||
| -/- | 40 | 29 | 80 | 59 | 0.007 | NS | ||
| -/+ | 42 | 30 | 17 | 36 | ||||
| +/- | 19 | 14 | NR | 68 | ||||
| +/+ | 31 | 21 | 31 | 31 | ||||
| Missing | 8 | 6 | ||||||
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor; NR, not reached; NS, not significant;
* overall significance as a prognostic factor